Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers
Status:
Completed
Trial end date:
2020-11-23
Target enrollment:
Participant gender:
Summary
This Phase 1 study aims to quantify the effects of cyclosporine, a broad transporter
inhibitor, and rifampicin, an OATP1B1/3 inhibitor, on verinurad pharmacokinetics (PK). The
study is conducted in accordance with Food and Drug Administration guidance on Clinical Drug
Interaction Studies, 2020. Verinurad will be developed as a fixed combination since it will
always be administered together with allopurinol.